Early identification of acute myocardial infarction by activated protein C-protein C inhibitor complex

Thrombosis Research

Volumn 118, Issue 2, 2006, Pages 213-219

  Bhiladvala, Pallonji ^a   Strandberg, Karin ^a   Stenflo, Johan ^a   Holm, Johan ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Activated protein C; Coagulation activity; Myocardial infarction; Protein C inhibitor

Indexed keywords

ACTIVATED PROTEIN C; CREATINE KINASE MB; PLASMINOGEN ACTIVATOR INHIBITOR 3; TROPONIN I;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DIAGNOSTIC ACCURACY; ELECTROCARDIOGRAM; EMERGENCY WARD; FEMALE; FLUOROMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL ASSAY; BLOOD COAGULATION TESTS; CREATINE KINASE; ELECTROCARDIOGRAPHY; EVALUATION STUDIES; FEMALE; FLUOROMETRY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROTEIN C; PROTEIN C INHIBITOR; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TROPONIN I;

EID: 33744533523     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.06.020     Document Type: Article

References (36)

1. Bhayana V., and Henderson A.R. Biochemical markers of myocardial damage. Clin Biochem 28 (1995) 1-29
2. Lindahl B. Markers of myocardial damage in acute coronary syndromes-therapeutic implications. Clin Chim Acta 311 (2001) 27-32
3. Dahlbäck B. Blood coagulation. Lancet 355 (2000) 1627-1632
4. Bertrand M.E., Simoons M.L., Fox K.A.A., Wallentin L.C., Hamm C.W., McFadden E., et al. The task force on the management of acute coronary syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 23 (2002) 1809-1840
5. Cannon C.P., Weintraub W.S., Demopoulos L.A., Vicari R., Frey M.J., Lakkis N., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
6. Wallentin, and FRISC II study investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study. FRagmin and fast revascularisation during instability in coronary artery disease. Lancet 354 (1999) 708-715
7. Derhaschnig U., Laggner A.N., Roggla M., Hirschl M.M., Kapiotis S., Marsik C., et al. Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. Clin Chem 48 (2002) 1924-1930
8. Mair J., Genser N., Maier J., Lechleitner P., Dienstl F., and Puschendorf B. Markers of activated coagulation for early diagnosis of acute myocardial infarction. Clin Chim Acta 267 (1997) 239-245
9. Ottani F., and Galvani M. Prognostic role of hemostatic markers in acute coronary syndromes patients. Clin Chim Acta 311 (2001) 33-39
10. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndrome. New Engl J Med 1992;326:242-250, 310-8.
11. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 90 (1994) 2126-2146
12. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 (2001) 365-372
13. Toschi V., Gallo R., Lettino M., Fallon J., Gertz S., Fernandez-Ortiz A., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95 (1997) 594-599
14. Dahlbäck B., and Stenflo J. The protein C anticoagulant system. In: Stamatopolous G., Majerus P.W., Perlmutter R.M., and Varmus H. (Eds). The molecular basis of blood coagulation. Third ed. (2001), W.B. Saunders 614-656
15. Stenflo J., and Dahlbäck B. Vitamin K-dependent proteins in blood coagulation. In: Stamatopolous G., Majerus P.W., Perlmutter R.M., and Varmus H. (Eds). The molecular basis of blood coagulation. Third ed. (2001), W.B. Saunders 579-613
16. Esmon C.T. The endothelial protein C receptor. Thromb Haemost 83 (2000) 639-643
17. Suzuki K., Deyashiki Y., Nishioka J., and Toma K. Protein C inhibitor: structure and function. Thromb Haemost 61 (1989) 337-342
18. Huntington J.A., Kjellberg M., and Stenflo J. Crystal structure of protein C inhibitor provides insights into hormone binding and heparin activation. Structure 11 (2003) 205-215
19. Marlar R.A., Kressin D.C., and Madden R.M. Contribution of plasma proteinase inhibitors to the regulation of activated protein C in plasma. Thromb Haemost 69 (1993) 16-20
20. 2-macroblobulin in patients with disseminated intravascular coagulation. Thromb Haemost 69 (1993) 448-453
21. Espana F., Gruber A., Heeb M.J., Hansson S.R., Harker L.A., and Griffin J.H. In vivo and in vitro complexes of activated protein C with two inhibitors in baboons. Blood 77 (1991) 1754-1760
22. Laurell M., Stenflo J., and Carlsson T.H. Turnover of I-protein C inhibitor and I-alfa-1-antritrypsin and their complexes with activated protein C. Blood 76 (1990) 2290-2295
23. Strandberg K., Bhiladvala P., Holm J., and Stenflo J. A new method to measure plasma levels of activated protein C in complex with protein C inhibitor in patients with acute coronary syndromes. Blood Coagul Fibrinolysis 12 (2001) 503-510
24. Strandberg K., Astermark J., Björgell O., Becker C., Nilsson P.E., and Stenflo J. Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis. Thromb Haemost 86 (2001) 1400-1408
25. Tanigawa M., Wada H., Minamikawa K., Wakita Y., Nagaya A., Mori T., et al. Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. Am J Hematol 49 (1999) 1-5
26. Espana F., Vicente V., Tabernero D., Sharrer I., and Griffin J.H. Determination of plasma protein C inhibitor and of two activated protein C inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 59 (1990) 593-608
27. Minamikawa K., Wada H., Wakita Y., Ohiwa M., Tanigawa M., Deguchi J., et al. Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism. Thromb Haemost 71 2 (1994) 192-194
28. Strandberg K., Kjellberg M., Erb E.M., Persson U., Mosher D.F., Villoutreix B.O., et al. Activated protein C-protein C inhibitor complex formation: characterisation of a neoepitope provides evidence for extensive insertion of a reactive center loop. Biochemistry 39 (2000) 15713-15720
29. Strandberg K., Kjellberg M., Knebel R., Lilja H., and Stenflo J. A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex i plasma. Thromb Haemost 86 (2001) 604-610
30. Strandberg K., Svensson A., and Stenflo J. Stabilyte tubes that contain strongly acidic citrate prevent in vitro complex formation between activated protein C and protein C inhibitor. Thromb Haemost 89 (2003) 947-949
31. Oldgren J., Linder R., Grip L., Siegbahn A., and Wallentin L. Coagulation activity and clinical outcome in unstable coronary artery disease. Arterioscler Thromb Vasc Biol 21 6 (2001) 1059-1064
32. Oldgren J., Wallentin L., Grip L., Linder R., Nörgard B.L., and Siegbahn A. Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease. Eur Heart J 24 (2003) 86-93
33. Oldgren J., Siegbahn A., Grip L., Linder R., Thygesen K., and Wallentin L. Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease. Thromb Haemost 91 (2004) 381-387
34. Bauer K.A. Activation markers of coagulation. Baillière's Best Pract Res Clin Haematol 12:3 (1999) 387-406
35. Holm J., Tödt T., Berntorp E., and Erhardt L.R. Failure of thrombolytic therapy in patients with myocardial infarction is associated with high levels of factor VII antigen. Thromb Haemost 79 (1998) 928-931
36. Fernandéz J.A., Gruber A., Heeb M.J., and Griffin J.H. Protein C pathway impairment in nonsymptomatic smokers. Blood Cells Mol Diseases 29 1 (2002) 73-82